Generate Biomedicines, Inc. (GENB)
Nasdaq · Pharmaceutical Preparations · Manufacturing · CIK 2100782 · fiscal year ends in Dec
Closing price $14.46 on 30 Oct 2026; 52-week range $11.21 to $20.38.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Market value
- $1.9B
- Cash
- $135.4M
- Debt
- $0
- Debt to equity
- 0.00
- Shares outstanding
- 128.3M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $6.3M | -$67.3M | -$0.52 |
| Q1 FY2026 | 31 Mar 2026 | $7.2M | -$61.4M | -$0.54 |
| Q2 FY2025 | 30 Jun 2025 | $10.1M | -$52.4M | -$1.94 |
| Q1 FY2025 | 31 Mar 2025 | $8.8M | -$41.7M | -$0.81 |
Company events
The newest 8-K filings of 4 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 26 Aug 2026 | 8-K | Investor update | 7.01, 9.01 |
| 6 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 7 May 2026 | 8-K | Results | 2.02, 9.01 |
| 2 Mar 2026 | 8-K | Bylaws or fiscal year change | 5.03, 9.01 |
Every filing
The newest filings with the SEC of 14 held.
| Filed | Form | Period |
|---|---|---|
| 26 Aug 2026 | 8-K | 25 Aug 2026 |
| 6 Aug 2026 | 10-Q | 30 Jun 2026 |
| 6 Aug 2026 | 8-K | 6 Aug 2026 |
| 7 May 2026 | 10-Q | 31 Mar 2026 |
| 7 May 2026 | 8-K | 7 May 2026 |
| 2 Mar 2026 | 8-K | 26 Feb 2026 |
| 27 Feb 2026 | S-8 | – |
| 26 Feb 2026 | EFFECT | – |
| 26 Feb 2026 | CERT | – |
| 24 Feb 2026 | 8-A12B | – |
| 23 Feb 2026 | S-1/A | – |
| 13 Feb 2026 | S-1/A | – |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 1 Sep 2026 | Arnold Frances, Director | Sale under a trading plan | 1,000 | $16.00 | $16.0K | 231,472 | 3 Sep 2026 |
| 4 Mar 2026 | Nally Michael, Chief Executive Officer | Purchase | 20,000 | $12.00 | $240.0K | 572,707 | 6 Mar 2026 |
| 2 Mar 2026 | Grous Beth, Chief People Officer | Purchase | 300 | $16.00 | $4.8K | 300 | 2 Mar 2026 |
| 2 Mar 2026 | Silvers Jason, President & CFO | Purchase | 500 | $16.00 | $8.0K | 500 | 2 Mar 2026 |
| 2 Mar 2026 | Silvers Jason, President & CFO | Purchase | 1,000 | $16.00 | $16.0K | 1,000 | 2 Mar 2026 |
| 2 Mar 2026 | Afeyan Noubar, Director | Purchase | 1,562,500 | $16.00 | $25.0M | 1,562,500 | 2 Mar 2026 |
| 2 Mar 2026 | Mendillo Jane L, Director | Purchase | 1,500 | $16.00 | $24.0K | 1,500 | 2 Mar 2026 |
| 2 Mar 2026 | Afeyan Noubar, Director | Purchase | 1,562,500 | $16.00 | $25.0M | 1,562,500 | 2 Mar 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 29 Oct 2026 | ARNOLD FRANCES, Director | 11,409 | $184.7K | 29 Oct 2026 |
| 2 Sep 2026 | ARNOLD FRANCES, Director | 32,210 | $520.6K | 2 Sep 2026 |
| 1 Sep 2026 | ARNOLD FRANCES, Director | 1,000 | $16.0K | 1 Sep 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 15 May 2026 | Flagship Pioneering Fund VI, L.P. | 13G | 48.9% | 62.7M |
| 15 May 2026 | Nally Michael | 13G | 5.2% | 6.9M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 8.9M | +20.41% | 7.99 |
| 30 Sep 2026 | 7.4M | +3.3% | 5.75 |
| 15 Sep 2026 | 7.2M | -3.7% | 7.24 |
| 31 Aug 2026 | 7.5M | +2.33% | 3.74 |
| 14 Aug 2026 | 7.3M | +0.15% | 15.09 |
| 31 Jul 2026 | 7.3M | +4.15% | 15.25 |
| 15 Jul 2026 | 7.0M | +18.06% | 9.38 |
| 30 Jun 2026 | 5.9M | +30.07% | 4.03 |
Funds that hold it
From each fund's latest Form 13F.
99 funds held it at 30 Jun 2026: 65 added and 10 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Flagship Pioneering, LLC | 62,673,117 | $1.1B | 0 |
| FMR LLC | 5,221,599 | $88.1M | +1,004,075 |
| Capital World Investors | 4,215,632 | $71.1M | +211,483 |
| Braidwell LP | 3,283,844 | $55.4M | -309,155 |
| Price T Rowe Associates Inc. | 2,156,627 | $36.4M | +46,994 |
| Norges Bank | 2,094,616 | $35.3M | – |
| ARCH Venture Management, LLC | 1,944,426 | $32.8M | 0 |
| HarbourVest Partners LLC | 1,722,210 | $29.1M | 0 |
| BlackRock, Inc. | 1,659,966 | $28.0M | +1,659,966 |
| Baker Bros. Advisors LP | 1,423,602 | $24.0M | 0 |
Peers
Companies in the same industry.
- Eli Lilly & Co. (LLY): revenue $86.5B, market value $1.33T
- Johnson & Johnson (JNJ): revenue $99.3B, market value $657.6B
- AbbVie Inc. (ABBV): revenue $64.4B, market value $521.0B
- Merck & Co., Inc. (MRK): revenue $66.6B, market value $368.9B
- Novartis AG (NVS): revenue $54.5B, market value $306.8B
- AstraZeneca PLC (AZN): revenue $58.7B, market value $289.5B
- Abbott Laboratories (ABT): revenue $46.6B, market value $183.8B
- Novo Nordisk A/S (NVO): revenue $46.8B, market value $178.6B
- Pfizer Inc. (PFE): revenue $63.7B, market value $173.8B
- Vertex Pharmaceuticals Inc. (VRTX): revenue $12.6B, market value $141.6B